Abstract: HLA class I molecules are frequently lost in a large variety of human carcinomas, possibly because of T-cell immune selection of major histocompatibility complex class I deficient tumor variants. We report that this phenomenon is also a frequent event in bladder carcinomas. Of a total of 72 bladder carcinomas, 72% of the tumors had at least one alteration in HLA class I expression. These altered HLA class I phenotypes were classified as total HLA class I loss (25%; phenotype I); HLA-A or/and HLA-B locus-specific loss (12%; phenotype III); and HLA class I allelic loss (35%; phenotype II or IV).
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Comparison of histopathological parameters with HLA class I expression showed a statistically significant relationship with the degree of differentiation and tumor recurrence. We studied 72 tumor tissue samples from patients diagnosed in our University Hospital between January 1998 and April 2000 as Key words: allele; bladder; carcinoma; class I; HLA; phenotype having superficial bladder carcinoma. The panel of mAbs we used defines monomorphic, locus-specific and HLA allele-specific class I determinants, and has been described (along with the techniques used) by Cabrera et al. (6) . We first grouped the patients into those who were positive (75%) and those who were heterogeneous (<75% expression) or negative (total loss) (25%) for W6/32 and anti-b 2 m mAbs. A second screening of the positive tumors identified those that were negative or heterogeneous for HLA-A, -B or -AB locus antigens (locus-specific loss; 12%) (Fig. 1) . The 45 tumors that were positive with monomorphic and locus-specific mAbs were then studied with the appropriate allele-specific mAbs. Twenty-five patients presented HLA allelic alteration (allele-specific loss); no HLA allelic alterations could be detected in the remaining 20 patients. However, mAbs were not available against some specificities present in these 20 patients, therefore some tumors may have had additional, undetectable allelic HLA losses. This sometimes makes it very difficult to define particular HLA class I alterations or, more importantly, to distinguish between different altered HLA class I phenotypes such as HLA allelic and HLA haplotype loss (phenotypes IV and II) (7) . Nevertheless, we found that in a large proportion (72%) of patients diagnosed with superficial bladder carcinoma, the tumor tissue had lost all or part of the HLA class I antigens ( (17) (18) (19) , but the results were sometimes contradictory and most studies defined HLA phenotype with Fig. 1 . HLA phenotype was studied in 72 patients diagnosed with bladder carcinoma. Expression was defined with immunohistological techniques on cryostatic tumor sections with a biotin-streptavidin amplified detection system. The panel of antibodies and the system used to score the results have been described previously (6).
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Tissue Antigens 2003: 62: 324-327 methods that underestimate the frequency of altered HLA class I expression (4, 19) . In their study of bladder tumors, Levin et al. (11) proposed HLA class I expression as a prognostic indicator, after finding a significant correlation between expression of HLA class I molecules and survival. However, the association between HLA class I antigens and transitional cell bladder carcinoma is not always clear (10) . The immunohistochemical study of HLA expression in solid tumors is limited by the lack of allele-specific mAbs that work with immunohistological techniques. Thus, patients are stratified for clinical outcome analysis into a loss group and a 'no known loss' group.
Other information about the clinical relevance of HLA loss come from observations of changes in tumor phenotype in relation to the natural history of the malignancy (20, 21) .
Our bivariate analysis of correlations between HLA tumor phenotype and clinical (age, primary or recurrent tumor, tumor size, treatment and follow up) and histological variables (type, pathological stage, and degree of cell anaplasia) revealed some interesting associations (1). HLA phenotype group was related with the degree of tumor differentiation: G2 and G3 tumors presented a higher rate of HLA class I losses than did G1 tumors, and this difference was statistically significant for G2 tumors (P < 0.001) (Fig. 2a) (2) . HLA phenotype group was related with the likelihood of tumor recurrence: most of the tumors that recurred presented with altered HLA class I antigen expression (P < 0.001) ( Correlations between clinical and histological variables and tumor HLA phenotype were sought with bivariate analysis. Greater statistical power was obtained by grouping the phenotypes into two categories: positive (no HLA alterations) and negative (total HLA loss, allelic loss, or locus loss). The power of each variable to predict tumor recurrence or progression was assessed with the multivariate Cox proportional hazards model (G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated).
